Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event

Vemurafenib, a selective inhibitor of the BRAF V600 mutation, is Food and Drug Administration and European Medicines Agency approved for the treatment of stage IV metastatic melanoma alone or in combination. Among the adverse effects, cutaneous toxicity is the most common. Most of these reactions s...

Full description

Bibliographic Details
Main Authors: Ana Filipe Monteiro, Margarida Rato, César Martins
Format: Article
Language:English
Published: Sociedade Portuguesa de Dermatologia e Venereologia 2018-10-01
Series:Revista da Sociedade Portuguesa de Dermatologia e Venereologia
Subjects:
Online Access:https://revista.spdv.com.pt/index.php/spdv/article/view/926